CNS 2008: Disorders/Therapeutics (Released 5/7/08)
NI Research announces the publication of the 2008 edition of this incomparable CNS industry overview, which incorporates a first-in-class evaluation of Big Pharma licensing skills and styles
There has never been a review of the Business Development and Licensing practices of the major pharmaceutical companies in the US and Europe with this level of detail and candor. The companies are discussed in terms of their culture, style, and 'user-friendliness' from a small partner viewpoint, and they are graded, from A to F. This review has been assembled from interviews with professionals on both sides of the large and small pharma divide, as well as our evaluations of the licensing performance over time of each company. For small and midsize companies thinking about strategy and fit, this information is indispensable. And for Big Pharma Business Development professionals, it offers an opportunity to find out how your organization, attitude, ability to relate, and performance are perceived
Reviews and grades covering BD operations for:
Abbott Laboratories
Astra Zeneca
Boehringer Ingelheim
Bristol Myers Squibb
Elan
Forest Laboratories
GlaxoSmithKline
Johnson & Johnson
Lilly
Lundbeck
Merck
Novartis
Pfizer
Roche
Sanofi-Aventis
Shire Pharmaceuticals
WyethThe second essential section of CNS 2008 compiles all of NI Research's comprehensive reviews of all major psychiatric and neurological indications, and the therapeutics programs under development. Addiction Disorders and Bipolar Disorder are included for the first time. All reviews are fully updated and revised as of May 5, 2008. This provides strategic planners and Business Development professionals with a complete review of the neuro and psychopharmaceutical universe of therapies in development, in a single searchable pdf. There is nothing else like CNS 2008 Disorders/Therapeutics, at any price.
Disorders reviewed:
Addiction ADHD
Alertness/EDS
Alzheimer’s
ALS
Anxiety
Bipolar Disorder Depression
Epilepsy
Huntington’s
Insomnia Memory Disorders
Migraine
MS
Neuropathic Pain
Nociceptive Pain
Parkinson’s
Schizophrenia
Spinal Cord Injury
Spinal Muscular Atrophy
Stroke Traumatic Brain Injury364 pages US$7500
Early-stage companies are invited to inquire about pricing options
California-based companies must pay 7.75% state sales tax.
Private CNS Company Review 2007-8 $3300Private CNS Company Review 2007-8 $3300[Add to Cart] [View Cart] To order online via secure server (orders are generally processed within 24 hours)
Fax to 760.753.6481 Mail to NI Research PO Box 1028 Cardiff CA 92007 760.230.2581
NeuroInvestment
(1yr: $1600 for email or pdf delivery, add $250 for both, add $50 for airmail delivery outside the US/Canada)
[Add to Cart] [View Cart] To order online via secure server (orders are generally processed within 24 hours)
Publication Order Form To download pdf file order form for fax or mail ordering
Contact
NI Research Inc.
PO Box 1028
Cardiff, CA 92007
orders@neuroinvestment.com 760.230.2581